Kornimate/medical-research-clean huggingface dataset:
pregnancy outcomes according to the gestational age of acquiring covid-19

Conditions: Covid19

Summary: a new coronavirus, called severe acute respiratory syndrome coronavirus 2 (sars-cov2) appeared in wuhan, china and it arrived to europe 2-3 months later. it infected millions of persons and led to the death of thousands until may 2020 where numbers of infections per week decreased significantly. however, starting september, number of infections started to escalate again and continued to rise until now. hundreds of good quality articles were published during this period to study the relationship and effects of this virus on pregnancy and vice versa, as well as to determine the adverse neonatal and obstetrical outcomes following the infection. in a case-control study using propensity score matching at the level of age, body mass index and comorbidities (diabetes, hypertension, asthma), pregnant women over 20 week's gestation had significantly higher risk for intensive care unit stay, endotracheal intubation, hospitalization for disease related symptoms and need for oxygen therapy. a new systematic review also demonstrated increased risk for icu admission in pregnant women compared to non-pregnant women and to non-infected pregnant women. on the other hand, many researchers have demonstrated that the rates of preterm delivery and cesarean delivery have increased as well, others reported a close relation between sars-cov2 infection and preeclampsia or preeclampsia like condition. enormous effort was done in order to understand adverse outcomes related to this infection, however, most studies included patients in the third or late second trimester. few studies stratified adverse outcomes of the patients according to the trimester of infection.


Eligibility criteria:
inclusion criteria: pregnant women with viable fetus after 10 weeks' gestation and known pregnancy outcome during the period starting on february 1st 2020 and ending on november 30th 2020. exclusion criteria: all ongoing pregnancies, those with unknown outcomes, those terminated medically or voluntary, as well as patients with spontaneous abortion before the 11th gestational week.
ultrasound-guided quadratus lumborum block for postoperative pain relief after cesarean delivery

Conditions: Postoperative Pain

Summary: the quadratus lumborum (ql) block is an ultrasound-guided technique described by rafael blanco in 2007. the nerves to the lower abdominal wall can be anesthetized by injecting local anesthetics close to the anterior border of the quadratus lumborum muscle. in our randomized, controlled, double-blinded study ultrasound-guided ql-blocks in 20 female patients after cesarean delivery will be compared with a placebo control group of 20 patients to investigate analgesic consumption, pain level, opioid related side effects and mobilization.


Eligibility criteria:
inclusion criteria: * patients with cesarean delivery * american society of anesthesiologists classification (asa) \< 3 * adequate communication skills * body mass index \< 32 exclusion criteria: * asa \> 2 * chronic pain * neurological illness/ neuropathy * contraindication against local anesthetics
total versus partial arytenoidectomy in bilateral vocal fold paralysis

Conditions: Airway Obstruction; Vocal Cord Paralysis

Summary: total arytenoidectomy is claimed to increase risk of aspiration and cause more voice loss than other operations performed for bilateral vocal fold paralysis (bvfp). however, objective evidence for such conclusion is lacking. there is no study comparing swallowing and voice after total and partial arytenoidectomy.

design: prospective, randomized, double-blind, case-control setting: tertiary, referral, university patients: twenty patients with bvfp intervention: endoscopic total and partial arytenoidectomy

Eligibility criteria:
inclusion criteria: * bilateral vocal fold paralysis exclusion criteria: * previously operated patients

Keywords: vocal cords vocal cord paralysis arytenoid cartilage
hallux valgus- radiological and clinical predictors for outcome after surgery

Conditions: Hallux Valgus

Summary: prospective observational study to evaluate the clinical and radiological predictors for outcome in hallux valgus (hv) corrective surgery.

hallux valgus (hv) is the most common deformity in the adult forefoot. characterizing and classifying hv primarily has been based on weightbearing radiographic imaging. understanding of this pathologic process has mainly been confined to two planes, where the dominating modality of choice has been assessment by antero-posterior (ap) and lateral radiographs. from these two projections, imaging parameters have developed to define the severity of hv. with this understanding as the basis for describing the deformity, more than 140 operative techniques have been described. although many of these techniques are of historical interest only, consistently favourable outcomes remain elusive even among more popular current techniques. hv corrective surgery is known to have mediocre results, with recurrence rate as high as 30-70%. unsuccessful treatment of the condition is amongst the most common in the norwegian patient injury compensation scheme. the variation in corrective techniques and the associated persistent and clinically significant rates of poor outcomes may indicate an incomplete treatment of the pathoanatomy of hv. numerous recent publications have proved that the hallux valgus deformity should be viewed as a three-dimensional deformity. these recent studies have also pointed out new radiological parameters in ap and axial view, focusing on the multiplanar understanding of the deformity. the key challenge of the hallux valgus foot is the lack of clear guidelines for choosing the best treatment to these large group of patients. there is of today no guidelines nor consensus considering the indication for surgical treatment of the hallux valgus deformity. it is not known how much nuisance the patient should present before surgery could be worthwhile. many studies have been made in the field of hv, but literature with the focus on comparing the surgical correction and the patient related clinical outcome is sparse and insufficient. in this project the investigators primary aim is to investigate radiological and clinical factors that predict outcome in participants operated for hallux valgus deformity.

Eligibility criteria:
inclusion criteria: * all adult patients accepted for hallux valgus surgery (mild, moderate, severe) at the øht will be asked to participate in the study exclusion criteria: * previous hallux valgus surgery in the same foot * lack of compliance * not available for follow-up * language difficulties (not able to communicate in english or norwegian)

Keywords: hallux valgus outcome predictors moxfq
anti-bcma car-nk therapy in relapsed or refractory multiple myeloma

Conditions: Multiple Myeloma, Refractory

Summary: immunotherapy has shown promise in the treatment of hematological malignancies, including multiple myeloma. one approach is car-nk cell therapy, which involves genetically modifying natural killer (nk) cells to target specific cancer antigens. while car-nk therapy offers advantages over car-t therapy, such as reduced immune system reactions and lower production time and cost, challenges remain in terms of antitumor efficacy and the tumor microenvironment. preclinical and early clinical studies have targeted various antigens, including bcma, with car-nk cells in multiple myeloma. to further investigate the potential of bcma-targeted car-nk cell therapy, this study aims to evaluate its safety and determine the maximum tolerated dose (mtd) in patients who have not responded to standard therapy.


Eligibility criteria:
inclusion criteria: 1. age 18-80 years with expected survival \> 3 months. 2. confirmed diagnosis of active multiple myeloma with detectable bcma expression in malignant cells. 3. relapsed or refractory disease with at least 2 prior lines of treatment, including a proteasome inhibitor and immunomodulator, without achieving significant efficacy. 4. measurable disease at screening according to imwg criteria, as defined by any of the following: serum monoclonal paraprotein (m-protein) level ≥1.0 g/dl or urine m-protein level being as defined； or light chain mm without measurable disease in the serum or the urine； serum immunoglobulin free light chain disease dl and abnormal serum immunoglobulin kappa/lambda free light chain ratio 5. ecog performance status of 0-1. 6. acceptable cardiac, liver, and kidney function. 7. signed written informed consent. exclusion criteria: 1. pregnant or lactating women. 2. uncontrolled active infection, hiv infection, or positive syphilis serology reaction. 3. active hepatitis b or hepatitis c infection. 4. recent or current use of glucocorticoids or other immunosuppressors. 5. severe cardiac, liver, renal insufficiency, diabetes, or other diseases. 6. participation in other clinical research in the past three months.

Keywords: car-nk therapy anti-bcma
neuropath comparative validation study plan

Conditions: Carpal Tunnel Syndrome (CTS)

Summary: the purpose of the study is to compare the performance of the neuropath automated nerve conduction test with the standard of care manual test in the diagnosis of entrapment neuropathies.


Eligibility criteria:
symptomatic inclusion criteria: * sensory symptoms (numbness and/or tingling) in at least 2 of digits 1,2,3 and 4, in at least one hand, for at least 1 month, prior to the start of the clinical study. the sensory symptoms may be intermittent or constant, but if constant, there must have been a period of time during which the symptoms were intermittent. the numbness and tingling may be accompanied by pain, but pain alone is not sufficient to meet this first inclusion criteria. * sensory symptoms (numbness and/or tingling) aggravated by at least 1 of the following: sleep, sustained hand or arm positioning, or repetitive actions of the hand. * sensory symptoms (numbness and/or tingling) mitigated by at least 1 of the following: changes in hand posture, shaking the hand, or use of a wrist splint. * if pain is present, the wrist, hand, and finger pain is greater than elbow, shoulder, or neck pain if there is pain in any or all of those locations. symptomatic exclusion criteria: * sensory symptoms exclusive or predominatly in the little finger (d5) (ulnar neuropathy). * neck pain or shoulder pain preceded the paresthesia in the digits (cervical radiculopathy and/or brachial plexopathy). * numbness and/or tingling in the feet that preceded or accompanied the sensory symptoms in the hands (polyneuropathy). * medical history and physical examination that indicates an explanation for the sensory symptoms which is more probable than cts. for example, digital neuropathy, median nerve pathology proximal to the carpal tunnel, ulnar neuropathy, radical neuropathy, brachial plexopathy, cervical radiculopathy, spinal cord, brainstem or brain pathology, or a polyneuropathy. * absence of 1st, 3rd, 4th or 5th digits * open wounds at the measurement sites * excessive sensitivity to electrical stimulation * median nerve injection in the past 30 days * prior carpal tunnel surgery * patients who are susceptible to radio frequency noise - such as patients with pacemakers or patients that have electrical stimulators of any sort. control subject inclusion criteria: * normal neurological examination control subject exclusion criteria: * absence of 1st, 3rd or 5th digits * open wounds at the measurement sites * excessive sensitivity to electrical stimulation * median nerve injection in the past 30 days * prior carpal tunnel surgery * reported history of cts, polyneuropathy, diabetes,renal failure, thyroid disease or vitamin b 12 deficiency * patients who are susceptible to radio frequency noise-such as patients with pacemakers or patients that have electrical stimulators of any sort.

Keywords: median neuropathy at the wrist (mnw)
stress management intervention for mothers of children with cancer

Conditions: Stress; Depression

Summary: to explore maternal biological (activation of the hypothalamic-pituitary-adrenal axis) and behavioral (smoking, sleep behavior, exercise and alcohol use) pathways of intervention-related decreases in inflammation. hypothesis: the intervention group will show decreased levels of cortisol and improved health behaviors from pre- to post-intervention when compared with the control group. we will also explore whether intervention-related changes in these parameters predict symptoms of illness. exploratory aim 2. to explore psychological pathways of intervention-related decreases in distress among mothers, including the perception of social support and the use of behavioral coping strategies that are components of the intervention. hypothesis: increases in perceived social support and use of active behavioral coping strategies will be associated with intervention-related decreases in symptoms of depression, anxiety and psychological stress.


Eligibility criteria:
inclusion criteria: * biologic, adoptive, or legal guardian mothers of children (birth to 17 years) who are within 6 weeks of being newly diagnosed with any cancer, with the exception of a central nervous system (cns) cancer or early stage lymphoma, recruited from the division of hematology and oncology, children's hospital of pittsburgh (chp) * no reported clinical history of psychotic or bipolar illness, neurological disorder (stroke, transient ischemic attacks, parkinson's disease, multiple sclerosis) or chronic disease known to influence immune function, including cardiovascular disease, cancer \[within the past 2 years\], or autoimmune disease * not taking medications that might alter responses to questionnaires or indices of immune function (including major sedatives or glucocorticoid, anti-inflammatory, anti-retroviral, or immunosuppressant medication) * fluency in english (i.e., have commonly used english in everyday speaking and reading for at least 10 years) * is at least 18 years of age * not working nightshifts exclusively. exclusion criteria: * mothers of children with cns cancers due to our belief that a psychosocial intervention tailored more specifically to the unique stressors inherent in this diagnosis is warranted * mothers of children with early stage lymphomas will be excluded because of their child's brief/mild treatment course * mothers whose child is older than 17 years will not be eligible; the upper age limit (17 years) was established based on referral patterns at the chp hematology/oncology department.

Keywords: maternal depression maternal psychosocial stress and distress maternal health outcomes social support pediatric cancer
effect of omega-3 fatty acids on oxidative stress and dyslipidemia in pediatric patients undergoing hemodialysis

Conditions: End Stage Renal Disease

Summary: the purpose of the study is to evaluate the effect of omega-3 fatty acids supplementation on pediatric patients undergoing hemodialysis via the measurement of the following before and after omega-3 administration:oxidative stress markers, inflammatory markers and serum lipids.


Eligibility criteria:
inclusion criteria: * patients between 8 and 18 years old * patients treated with hd for at least 6 months exclusion criteria: * patients with malignancy and active inflammatory disease. * patients who received vitamin e or any antioxidant treatment during the past 3 months.

Keywords: omega-3 fatty acids hemodialysis oxidative stress dyslipidemia
pulmonary artery remodelling with bosentan

Conditions: Hypertension, Pulmonary

Summary: the main purpose of this study is to investigate whether bosentan (tracleer®) affects the wall thickness of the pulmonary arteries in patients with idiopathic pulmonary arterial hypertension (ipah) and pah related to systemic sclerosis (pah-ssc). the second purpose is to investigate if bosentan affects the enlargement of small vessels in the lungs in response to natural chemicals in patients with ipah and pah-ssc.


Eligibility criteria:
inclusion criteria : · men or women \>18 years of age.· * symptomatic (modified nyha class iii) ipah or pah-ssc· * pah confirmed by right heart catheterization performed within 3 months before enrolment mpap \> 25 mmhg, pcwp \ 3 mmhg/l/min. * women of childbearing potential must have a negative pre-treatment pregnancy test and use a reliable method of contraception during study treatment and for 3 months after study treatment termination. * bosentan naïve patients exclusion criteria : · pah other than ipah or pah-ssc * significant vasoreactivity during right heart catheterization defined as a fall in mpap to \ = 10 mmhg and with a normal cardiac index (\>= 2.5 l/min.m2)· severe obstructive lung disease: fev1/fvc \< 0.5 * severe restrictive lung disease: tlc \< 0.7 of normal predicted value * hemoglobin \<75% of the lower limit of the normal range· systolic blood pressure \< 85 mmhg * body weight \< 40 kg * pregnancy or breast-feeding * moderate to severe hepatic impairment, i.e., child-pugh class b or c. * baseline aminotransferases, i.e., aspartate aminotransferases (ast) and/or alanine aminotransferases (alt) \> 3 times the upper limit of the normal (uln) range. * treatment for ipah or pah-ssc within 1 month before start of study treatment, excluding warfarin and acute administration of vasodilators for vascular reactivity testing during heart catheterization. * treatment with epoprostenol or other prostacyclin analogs for ipah or pah-ssc within 1 month before start of study treatment * treatment with glibenclamide (glyburide), fluconazole ketoconazole or ritonavir within 1 week before start of study treatment. * current treatment with cyclosporine a or tacrolimus * hypersensitivity to bosentan or any of the excipients of its formulation. * patient who received an investigational drug (such as sildenafil) within 3 months before start of study treatment * conditions that prevent compliance with the protocol or adherence to therapy.

Keywords: pulmonary arterial artery hypertension systemic sclerosis scleroderma remodelling bosentan tracleer intravascular
anticoagulant treatments and percutaneous coronary angioplasty

Conditions: Coronary Artery Disease

Summary: the purpose of this study is to determine whether adjunction of intravenous anticoagulant therapy (enoxaparin, hnf, bivalirudin) to antiaggregation with clopidogrel and aspirin improves in-hospital results of percutaneous transluminal coronary angioplasty (ptca) in selected patients.

* background : we don't know if using iv anticoagulant therapy is necessary for percutaneous coronary angioplasty in stable patients. * purpose : to compare efficacy and security of use or not of different anticoagulant treatments during percutaneous coronary angioplasty in patients with double antiaggregant therapy. * abstract : in stable patients pretreated with double antiaggregant therapy use of iv anticoagulants has not been yet evaluated during angioplasty. in this prospective randomized trial we want to compare in such patients the efficacy and security of the administration of iv heparin, iv enoxaparin, iv bivalirudin and no use of anticoagulant during coronary angioplasty. we will evaluate in each group ischaemic events (clinic, ecg and biology) and haemorrhagic events (clinic, biology) with a one month follow up. * primary outcome: ischaemic events via troponin ic measurements during 24 hours post procedure. * secondary outcomes: haemorrhagic events : clinical and biological evaluation (hb, ht, timi score) * study design : monocentric randomized clinical trial type therapeutic equivalence phase iv. * interventions : in patients prepared with therapeutic association (aspirin clopidogrel) comparison between use or no of anticoagulant (iv heparin, iv enoxaparin or iv bivalirudin). * number of subjects : 120 per group (total of 480). * statistical analysis : multivariate analysis with logistic regression models : each end point (troponin ic increase, haemoglobin decrease, ...) will be explicated with treatment group and other covariates (sex, age, creatinine, ...).

Eligibility criteria:
inclusion criteria: * stable angina pectoris or silent ischaemia exclusion criteria: * instable angina or acs (acute coronary syndrome)

Keywords: ptca antiaggregant therapy anticoagulant therapy
evaluation of hall technique and atraumatic restorative treatment for management of caries in the primary dentition

Conditions: Primary Dental Caries

Summary: the aim of the present study is to evaluate both hall technique and atraumatic restorative technique in comparison to the conventional restorative technique in the management of carious lesions in primary molars.

this study is a three arm randomized controlled clinical trial. eligible children will be selected from the outpatient clinic of pediatric dentistry and public health department, faculty of dentistry, alexandria university after securing necessary consents. one hundred and fifty five teeth will be randomly allocated into 3 groups fifty two each. group i will be assigned to hall technique group ii will be assigned to atraumatic restorative treatment using glass ionomer cement, and group iii will be assigned to a conventional restoration and will serve as a control.

Eligibility criteria:
inclusion criteria: * children free of any systemic disease or special health care needs. * cooperative children ( positive/ definitely positive) according to frankl's behavior rating scale. * children who are willing to participate in the study * tooth inclusion criteria: * primary molar teeth with occlusal or occlusoproximal carious lesions into dentin (international caries detection and assessment system) (icdas) codes: 3-5 * absence of clinical signs or symptoms of irreversible pulpitis * absence of fistula or abscess near the selected tooth clinically and radiographically * absence of spontaneous pain * absence of pulp exposure * absence of pathological mobility by placing the points of a pair of tweezers in an occlusal fossa, and gently rocking the tooth bucco-lingually. exclusion criteria: * clinical signs and symptoms of irreversible pulpilitis. * tooth mobility * spontaneous pain